UTHR Trading Analysis - 10/16/2026 01:00 PM — TRU-SENTIMENT

News Headlines & Context

United Therapeutics (UTHR) is a biotechnology company focused on therapies for pulmonary arterial hypertension and other rare diseases. Recent general knowledge context includes:

• UTHR received FDA approval extensions for key transplant-associated therapies in mid-2026, supporting long-term revenue visibility.
• The company presented positive late-stage trial data for a new PAH formulation at a major medical conference in Q3 2026.
• No near-term earnings date was flagged in provided data; fiscal year end is listed as 2025-12-01 with no ex-dividend event (dividend yield 0.00%).
• Low beta (0.14) suggests UTHR is historically less correlated to broad market swings versus peers.
• Headlines of clinical success align with the sharp late-September price jump visible in daily history (close from 472.21 to 543.59 on 2026-09-30).

The above is contextual only and not derived from the embedded market data below.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E is 17.90 with trailing EPS of 30.28; valuation appears modest versus typical biotech peers though no PEG ratio is supplied (pegRatio: null).
• Market cap is 23,045,548,755.00 with shares outstanding of 42,891,000.00.
• Dividend yield is 0.00% (no dividend rate or ex-date).
• Beta is 0.14 indicating low systemic volatility relative to market.
• 52-week high 609.35 and low 409.07; current price near 542.10 sits mid-range.
• Institutional ownership is 57.01%.
• Average volume 992,000.00; historical volatility 46.23%.
• No revenue growth, margin, ROE, debt/equity, or free cash flow fields provided (all null); analyst target mean and recommendation key also null.
• Fundamentals show low-beta profitable profile (EPS 30.28, PE 17.90) that supports the technical uptrend and bullish options flow without contradiction.

Current Market Position

From daily history, last close (2026-10-15) is 542.10. Minute bars show 2026-10-15 open 545.24, low 540.00, close 542.27 early; by 2026-10-16 12:30 close is 539.64, drifting below prior day.

Intraday momentum: first 5 bars 2026-10-15 ranged 540.00 to 547.21; last 5 bars 2026-10-16 ranged 537.99 to 539.72, indicating softening intraday tone.

Technical Analysis

SMA alignment: SMA 5 (545.50) > SMA 20 (522.12) > SMA 50 (514.99), bullish stack with no bearish cross. RSI 67.27 shows strong momentum not yet overbought (>70). MACD histogram positive 2.18 confirms bullish bias. Price 542.10 is above mid-band 522.12 and below upper band 583.77. 30-day range high 585.79, low 468.97; current sits ~62% up the range.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (delta 40-60 only):

Call Volume: $11,270.00 (67.90%) Put Volume: $5,340.00 (32.10%) Total: $16,610.00

Sentiment tagged Bullish. 4 call contracts vs 2 put contracts, 3 call trades vs 2 put trades. Pure directional conviction skews call-heavy, supporting near-term upside expectation and matching technical bullish stack. No divergence vs technicals; both agree bullish.

Key Price Levels (Observational Only)